Medical liability reform is gaining more attention as critical for ensuring access to care and spurring development of new medical treatments.
WASHINGTON, D.C.-Medical liability reform is gaining more attention as critical for ensuring access to care and spurring development of new medical treatments.
A liability protection provision, for example, was included in legislation that Congress approved in December to launch the administration's Pandemic Influenza plan. Language providing liability protection for manufacturers of pandemic countermeasures was added to the $453 billion 2006 defense appropriations bill, which provides $3.8 billion to support national emergency preparedness and the development of new vaccines and drugs.
BROAD MEASURE
Separately, an analysis of emergency medical care across the country down-rates many states due to their poor "medical liability environment," according to the American College of Emergency Physicians (ACEP).
In developing a report card on the nation's emergency medicine capabilities, ACEP gave points to states that have adopted caps on non-economic damage awards.
The report card also rates states on three other measures: access to emergency care; quality and patient safety; and public health and injury prevention.
These categories evaluate a state's percentage of uninsured; availability of hospital beds and emergency specialists; access to ambulances and 911 services; local injury prevention programs; and immunization rates. Only a handful of states received "B" ratings, while most scored only "Cs" and "Ds."
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More